With the advent of targeted therapy and immunotherapies, especially FDA-approved therapies for stage IV EGFR-positive NSCLC, a rapid decline in mortality from NSCLC has been observed in recent decades4,5. This evidence concerns the gene EGFR and non-small cell lung carcinoma.